Edwards Lifesciences Corporation $EW Stake Boosted by Wilson Asset Management International PTY Ltd.

Wilson Asset Management International PTY Ltd. increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 5.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 146,506 shares of the medical research company’s stock after purchasing an additional 7,713 shares during the quarter. Edwards Lifesciences makes up 2.8% of Wilson Asset Management International PTY Ltd.’s investment portfolio, making the stock its 17th largest holding. Wilson Asset Management International PTY Ltd.’s holdings in Edwards Lifesciences were worth $11,458,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $26,000. SouthState Corp bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $27,000. Global X Japan Co. Ltd. grew its stake in shares of Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock valued at $29,000 after buying an additional 216 shares in the last quarter. Tradewinds Capital Management LLC grew its stake in shares of Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock valued at $29,000 after buying an additional 205 shares in the last quarter. Finally, Rossby Financial LCC bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at approximately $29,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Wells Fargo & Company boosted their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a report on Thursday, August 7th. Truist Financial boosted their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a “hold” rating in a report on Friday, July 25th. Royal Bank Of Canada upped their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Daiwa America upgraded Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $87.06.

Edwards Lifesciences Trading Down 1.4%

Shares of EW opened at $72.94 on Tuesday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $64.89 and a 12-month high of $83.00. The firm has a market capitalization of $42.82 billion, a PE ratio of 10.49, a price-to-earnings-growth ratio of 3.55 and a beta of 1.05. The stock’s fifty day simple moving average is $77.95 and its 200-day simple moving average is $76.18.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.